Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Translation elongation factor 2 (eEF2) in Plasmodium falciparum is an essential GTPase enzyme responsible for catalyzing the translocation of the ribosome along mRNA during protein synthesis. It is a validated antimalarial drug target, with inhibitors like M5717 showing potent activity by disrupting protein synthesis. Mutations in eEF2 can confer drug resistance, making it a crucial factor in drug development and deployment strategies against malaria.
Inhibition of eEF2 function, halting ribosomal translocation and protein synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Translation elongation factor 2 (Plasmodium falciparum) (eEF2).